ET-NK cells (ET-NK/T-DM1), into which T-DM1 (trastuzumab emtansine) has been introduced, were tested for their anticancer effects in the HER2-positive cancer cell lines SK-BR-3 and Calu-3. The gene discussed is ERBB2; the disease is cancer.